FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080950269> ?p ?o ?g. }

• W2080950269 endingPage "34" @default.
• W2080950269 startingPage "23" @default.
• W2080950269 abstract "Preference for and acceptability of a drug are crucial for complianceand hence optimal treatment of diseases that require long-term management (eg, osteoporosis). The preference for and acceptability of a chewable tablet containing calcium and vitamin D 3 and a dose-comparable effervescent powder were assessed in a Phase 4, randomized, open-label, crossover trial in 5 European countries (Sweden, Finland, Belgium, the Netherlands, and Greece). The aim of the present analysis was to compare the preference for and acceptability, including tolerability, of these 2 formulations based on the Belgian results of the previously mentioned study. Patients were recruited from 3 osteoporosis units and universityhospitals in Brussels, Liege, and Ghent, Belgium. Adult patients at risk for calcium and vitamin D deficiencies were enrolled. The study drugs included 2 formulations of a dietary supplement containing a combination of calcium plus vitamin D 3 : chewable tablets (calcium carbonate, 1250 mg; vitamin D 3 , 400 IU) (A) and effervescent powder (calcium carbonate, 1250 mg; vitamin D 3 , 440 IU) (B). Patients were randomly assigned to receive 1 of 2 treatment sequences: AB or BA. Both formulations were given PO BID for 14 days, with a switch to the alternate formulation occurring on day 15 of the study. Preference and acceptability were assessed using 2 questionnaires: one assessed 5 variables of acceptability using 11-point scales, and the other assessed preference using yes/no questions. Compliance and tolerability were recorded throughout the study, with unused dose counts and recording of adverse events (AEs), respectively. The study comprised 200 patients, 199 of whom received at least 1 dose of study medication and were included in the intent-to-treat analysis (174 women, 25 men; mean age, 66 years [range, 30–87 years]). Preference data were available in 178 patients, 129 of whom (72.5%) preferred the chewable tablet compared with 34 (19.1%) who preferred the effervescent powder and 15 (8.4%) who had no preference (both, P < 0.001 vs tablet). The preference for the tablet was based on consistently and significantly higher mean scores on all 5 variables of acceptability (all, P < 0.001). The most common AEs were gastrointestinal (tablet, 27/192 patients [14.1%]; powder, 31/190 patients [16.3%]). Eighteen patients (9.0%) discontinued the trial due to ≥1 AE (12 receiving the tablet and 6 receiving the powder). In this study of preference for and acceptability of 2 formulations (chewable tablet and effervescent powder) of a dietary supplement containing a combination of calcium plus vitamin D 3 in Belgian adults at risk for calcium and vitamin D deficiencies, the chewable tablet was preferred by a significant majority. Based on 5 variables, the tablet was found to be significantly more acceptable than the powder. Tolerability was similar between the 2 formulations." @default.
• W2080950269 created "2016-06-24" @default.
• W2080950269 creator A5040175994 @default.
• W2080950269 creator A5050173865 @default.
• W2080950269 creator A5064793416 @default.
• W2080950269 date "2005-01-01" @default.
• W2080950269 modified "2023-10-17" @default.
• W2080950269 title "Preference for and acceptability of twoformulations of a dietary supplement containing calcium plus vitamin D3: A randomized, open-label, crossover trial in adult patients with calcium and vitamin D deficiencies" @default.
• W2080950269 cites W1553549387 @default.
• W2080950269 cites W1915528688 @default.
• W2080950269 cites W1983035974 @default.
• W2080950269 cites W1992279725 @default.
• W2080950269 cites W2009014831 @default.
• W2080950269 cites W2017704668 @default.
• W2080950269 cites W2080808060 @default.
• W2080950269 cites W2089817185 @default.
• W2080950269 cites W2099633645 @default.
• W2080950269 cites W2314110838 @default.
• W2080950269 doi "https://doi.org/10.1016/j.curtheres.2005.03.003" @default.
• W2080950269 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3964541" @default.
• W2080950269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24672109" @default.
• W2080950269 hasPublicationYear "2005" @default.
• W2080950269 type Work @default.
• W2080950269 sameAs 2080950269 @default.
• W2080950269 citedByCount "6" @default.
• W2080950269 countsByYear W20809502692016 @default.
• W2080950269 countsByYear W20809502692017 @default.
• W2080950269 countsByYear W20809502692020 @default.
• W2080950269 crossrefType "journal-article" @default.
• W2080950269 hasAuthorship W2080950269A5040175994 @default.
• W2080950269 hasAuthorship W2080950269A5050173865 @default.
• W2080950269 hasAuthorship W2080950269A5064793416 @default.
• W2080950269 hasBestOaLocation W20809502691 @default.
• W2080950269 hasConcept C124490489 @default.
• W2080950269 hasConcept C126322002 @default.
• W2080950269 hasConcept C142724271 @default.
• W2080950269 hasConcept C168563851 @default.
• W2080950269 hasConcept C197934379 @default.
• W2080950269 hasConcept C204787440 @default.
• W2080950269 hasConcept C27081682 @default.
• W2080950269 hasConcept C2776940978 @default.
• W2080950269 hasConcept C2778375690 @default.
• W2080950269 hasConcept C519063684 @default.
• W2080950269 hasConcept C71924100 @default.
• W2080950269 hasConcept C87813604 @default.
• W2080950269 hasConceptScore W2080950269C124490489 @default.
• W2080950269 hasConceptScore W2080950269C126322002 @default.
• W2080950269 hasConceptScore W2080950269C142724271 @default.
• W2080950269 hasConceptScore W2080950269C168563851 @default.
• W2080950269 hasConceptScore W2080950269C197934379 @default.
• W2080950269 hasConceptScore W2080950269C204787440 @default.
• W2080950269 hasConceptScore W2080950269C27081682 @default.
• W2080950269 hasConceptScore W2080950269C2776940978 @default.
• W2080950269 hasConceptScore W2080950269C2778375690 @default.
• W2080950269 hasConceptScore W2080950269C519063684 @default.
• W2080950269 hasConceptScore W2080950269C71924100 @default.
• W2080950269 hasConceptScore W2080950269C87813604 @default.
• W2080950269 hasIssue "1" @default.
• W2080950269 hasLocation W20809502691 @default.
• W2080950269 hasLocation W20809502692 @default.
• W2080950269 hasLocation W20809502693 @default.
• W2080950269 hasLocation W20809502694 @default.
• W2080950269 hasLocation W20809502695 @default.
• W2080950269 hasOpenAccess W2080950269 @default.
• W2080950269 hasPrimaryLocation W20809502691 @default.
• W2080950269 hasRelatedWork W1857897108 @default.
• W2080950269 hasRelatedWork W1989111914 @default.
• W2080950269 hasRelatedWork W1997555470 @default.
• W2080950269 hasRelatedWork W2059480547 @default.
• W2080950269 hasRelatedWork W2083490906 @default.
• W2080950269 hasRelatedWork W2088202054 @default.
• W2080950269 hasRelatedWork W2106814035 @default.
• W2080950269 hasRelatedWork W2388518409 @default.
• W2080950269 hasRelatedWork W2413727584 @default.
• W2080950269 hasRelatedWork W3197305493 @default.
• W2080950269 hasVolume "66" @default.
• W2080950269 isParatext "false" @default.
• W2080950269 isRetracted "false" @default.
• W2080950269 magId "2080950269" @default.
• W2080950269 workType "article" @default.